It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
The inspection was carried out from January 28 to February 1, 2025
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Subscribe To Our Newsletter & Stay Updated
